Mangalam Drugs & Organics Share Price | Mangalam Drugs & Organics Stock Screener
MANGALAM
Pharmaceuticals
Share Price NSE
₹29.27
▲
1.39 (4.99%)
Share Price BSE
₹30.48
▼
-0.09 (-0.29%)
As of March 4, 2026, the Mangalam Drugs & Organics share price (NSE: MANGALAM) is ₹29.27 on NSE and ₹30.48 on BSE, up 4.99% from the previous close, with shares trading between ₹26.54 and ₹29.27, and a 52-week range of ₹23.78–₹92.46.
Check MANGALAM annual price range for the annual price range and momentum.
Use the Mangalam Drugs & Organics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Mangalam Drugs & Organics Market Cap
₹47.41 Cr.
MANGALAM P/E Ratio (TTM)
-1.54
Mangalam Drugs & Organics P/B Ratio
0.40
EPS (TTM)
₹4.25
Dividend Yield
-
Debt to Equity
0.73
MANGALAM 52 Week High
₹92.46
Mangalam Drugs & Organics 52 Week Low
₹23.78
Operating Margin
-8.00%
Profit Margin
-19.40%
MANGALAM Revenue (TTM)
₹67.00
EBITDA
₹-6.00
Net Income
₹-13.00
Total Assets
₹315.00
Total Equity
₹103.00
Mangalam Drugs & Organics Share Price Chart
Screen Mangalam Drugs & Organics share price with an interactive chart. Analyse MANGALAM price trends and volatility across different timeframes.
Mangalam Drugs & Organics Company Profile - Fundamental Screener
Screen Mangalam Drugs & Organics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for MANGALAM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE584F01014
Mangalam Drugs & Organics Balance Sheet Screener
Screen MANGALAM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 |
|---|---|---|---|
| Assets | |||
| Total Assets | 315 | 366 | 334 |
| Current Assets | 156 | 199 | 176 |
| Fixed Assets | 159 | 163 | 148 |
| Liabilities | |||
| Total Liabilities | 0 | 0 | 0 |
| Current Liabilities | 15 | 26 | 34 |
| Non-Current Liabilities | 0 | 0 | 0 |
| Shareholders' Equity | |||
| Total Equity | 103 | 149 | 136 |
| Share Capital | 16 | 16 | 16 |
| Reserves & Surplus | 87 | 133 | 120 |
Mangalam Drugs & Organics Income Statement Screener - Profit & Revenue Analysis
Screen Mangalam Drugs & Organics income statement and profit fundamentals.
Analyze MANGALAM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Mangalam Drugs & Organics share price evaluation.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 73 | 57 | 49 | 59 | 102 | 77 | 80 | 89 | 97 |
| Expenses | 73 | 63 | 62 | 52 | 60 | 91 | 68 | 71 | 80 | 90 |
| EBITDA | -6 | 10 | -5 | -3 | -1 | 12 | 8 | 9 | 9 | 7 |
| Operating Profit % | -8.00% | 14.00% | -8.00% | -6.00% | -3.00% | 11.00% | 11.00% | 11.00% | 10.00% | 7.00% |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Interest | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 3 |
| Profit Before Tax | -13 | 2 | -13 | -13 | -10 | 4 | 1 | 1 | 1 | 0 |
| Tax | 0 | 2 | 1 | -5 | 0 | 0 | -2 | -2 | 0 | -1 |
| Net Profit | -13 | 0 | -14 | -7 | -10 | 4 | 3 | 3 | 1 | 1 |
| EPS | -8.48 | 0.04 | -8.72 | -4.64 | -6.21 | 2.23 | 1.70 | 1.70 | 0.81 | 0.31 |
Mangalam Drugs & Organics Cash Flow Screener - Liquidity Fundamentals
Screen MANGALAM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March |
|---|---|---|
| Operating Activities | 43 | 4 |
| Investing Activities | -20 | -12 |
| Financing Activities | -22 | 5 |
| Net Cash Flow | 1 | -3 |
Mangalam Drugs & Organics Shareholding Pattern Screener
See Mangalam Drugs & Organics shareholding pattern with promoter, FII, and DII holdings.
Check Mangalam Drugs & Organics promoter holding and ownership changes for MANGALAM on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 35.65% | 50.30% | 50.30% | 50.30% | 35.64% | 50.32% | 50.32% | 50.30% |
| FII Holding | 0.32% | 0.47% | 0.53% | 0.11% | 0.13% | 0.26% | 0.21% | 0.11% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 60.14% | 44.55% | 44.53% | 45.00% | 57.52% | 44.22% | 44.70% | 44.91% |
| Other Holding | 3.89% | 4.68% | 4.63% | 4.59% | 6.70% | 5.20% | 4.77% | 4.67% |
| Shareholder Count | 24,781 | 19,697 | 19,728 | 19,881 | 21,227 | 19,173 | 19,312 | 19,508 |
Mangalam Drugs & Organics Share Dividend Screener - Share Yield Analysis
Check Mangalam Drugs & Organics dividend history with payout and yield data.
View Mangalam Drugs & Organics dividend details including ex-dates and amounts for MANGALAM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.50 | 0.92% |
| 2017-March | ₹0.00 | 0.00% |
| 2016-March | ₹0.00 | 0.00% |
Mangalam Drugs & Organics Stock Index Membership
See which indices include Mangalam Drugs & Organics stock.
Check MANGALAM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Mangalam Drugs & Organics Market Events Screener - Corporate Actions
Get Mangalam Drugs & Organics corporate actions including splits, bonuses, and buybacks.
Check Mangalam Drugs & Organics stock events that may affect MANGALAM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -7.92% | ||
| Annual General Meeting | NA | -4.57% | ||
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | 1.50% |
| 2026-01-15 | 2026-01-15 | Quarterly Result Announcement | NA | 33.96% |
| 2025-11-20 | 2025-11-20 | Quarterly Result Announcement | NA | -17.31% |
| 2025-08-12 | 2025-08-12 | Extraordinary General Meeting | NA | -9.85% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -4.03% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 4.63% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | 1.61% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -4.83% |
Mangalam Drugs & Organics Competitors Screener - Peer Comparison
Screen MANGALAM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Mangalam Drugs & Organics Company Announcements - News Screener
Screen MANGALAM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure | - | |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-20 | Approval Of Audited Financial Results For The Quarter Ended 31St March 2026 | - |
| 2026-05-20 | Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th May 2026 For Declaration Of Audited Financial Results(Standalone & Consolidated) Of The Company For The Quarter And Year Ended 31St March 2026 | - |
| 2026-05-12 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 14Th May 2026 Inter-Alia To Approve Audited Financial Results(Standalone & Consolidated) Of The Company For The Period Ended 31St March 2026 | - |
| 2026-04-29 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-29 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-29 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-17 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-04-17 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-04-16 | Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure | - |
| 2026-04-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-03-26 | Board Meeting Outcome for Outcome Of Board Meeting For Resignation Tendered By CS Anuradha Pandey Accepted By The Board Approval For The Appointment Of New Company Secretary Nominated By NRC Ms. Shweta Patel. | - |
| 2026-03-24 | Board Meeting Intimation for Board Meeting Intimation To Be Held On 26Th March 2026 | - |
| 2026-03-24 | Closure of Trading Window | - |
| 2026-03-18 | Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure | - |
| 2026-03-18 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-03-18 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |